natgillin/translations-raw huggingface dataset:
In patients with mild to moderate hepatic impairment (Child-Pugh A and B), the clearance of vardenafil was reduced in proportion to the degree of hepatic impairment.
U bolesnika s blagim do umjerenim oštećenjem funkcije jetre (Child-Pugh A i B) klirens vardenafila bio je smanjen proporcionalno stupnju oštećenja funkcije jetre.
In patients with mild to moderate hepatic impairment telmisartan/amlodipine should be administered with caution.
Kod bolesnika s blagim do umjerenim oštećenjem jetre, kombinaciju telmisartan/amlodipin treba primjenjivati s oprezom.
In patients with mild to moderate hepatic impairment the posology should not exceed Actelsar HCT 40 mg/12.5 mg once daily.
Kod bolesnika s blagim do umjerenim oštećenjem jetre doza ne smije prelaziti Actelsar HCT 40 mg/12,5 mg jedanput dnevno.
In patients with mild to moderate hepatic impairment the posology should not exceed Kinzalkomb 40 mg/12.5 mg once daily.
Kod bolesnika s blagim do umjerenim oštećenjem jetre doza ne smije prelaziti Kinzalkomb 40 mg/12,5 mg jedanput dnevno.
In patients with mild to moderate hepatic impairment the posology should not exceed MicardisPlus 40 mg/12.5 mg once daily.
Kod bolesnika s blagim do umjerenim oštećenjem jetre doza ne smije prelaziti MicardisPlus 40 mg/12,5 mg jedanput dnevno.
In patients with mild to moderate hepatic impairment the posology should not exceed PritorPlus 40 mg/12.5 mg once daily.
Kod bolesnika s blagim do umjerenim oštećenjem jetre doza ne smije prelaziti PritorPlus 40 mg/12,5mg jedanput dnevno.
In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Copalia HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2).
U bolesnika s blagim do umjerenim oštećenjem jetre, bez kolestaze, najviša preporučena doza valsartana je 80 mg te Copalia HCT stoga nije pogodan za ovu skupinu bolesnika (vidjeti dijelove 4.3, 4.4 i 5.2).
In patients with mild to moderate hepatic impairment, the posology should not exceed 40 mg once daily (see section 4.4).
U bolesnika s blagim do umjerenim oštećenjem jetre doza ne smije prelaziti 40 mg jednom dnevno (vidjeti dio 4.4).
In patients with mild to moderate renal impairment, reduced doses should be prepared as instructed below.
U bolesnika s blagim do umjerenim oštećenjima bubrega, potrebno je pripremiti smanjene doze prema dolje navedenim uputama.
In patients with mild to moderate renal impairment, reduced Zoledronic acid medac 4 mg/100 ml solution for infusion doses are recommended (see section “Posology” above and section 4.4).
U bolesnika s blagim do umjerenim oštećenjem funkcije bubrega preporučuju se snižene doze Zoledronatne kiseline medac 4 mg/100 ml otopine za infuziju (vidjeti dio “Doziranje” iznad i dio 4.4).
In patients with mild to moderate renal impairment, the pharmacokinetic profile of zaleplon is not significantly different than that in healthy subjects.
U bolesnika s blagim do umjerenim oštećenjem funkcije bubrega, farmakokinetički profil zaleplona nije značajno drugačiji od onog u zdravih ispitanika.
In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g. ibuprofen) or aspirin at higher dose should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).
U bolesnika s blagim do umjerenim zatajenjem bubrega (klirens kreatinina od 45 do 79 ml/min) mora se izbjegavati istodobna primjena NSAIL-a (npr. ibuprofena) ili viših doza acetilsalicilatne kiseline dva dana prije, na sam dan i dva dana nakon primjene pemetrekseda (vidjeti dio 4.4).
In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g., ibuprofen) or aspirin at higher doses should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).
U bolesnika s blagim do umjerenim zatajenjem bubrega (klirens kreatinina od 45 do 79 ml/min) mora se izbjegavati istodobna primjena NSAIL-a (npr. ibuprofena) ili viših doza acetilsalicilatne kiseline dva dana prije, na sam dan i dva dana nakon primjene pemetrekseda (vidjeti dio 4.4).
In patients with mild to moderate renal insufficiency eligible for pemetrexed therapy NSAIDs with long elimination half-lives should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration (see section 4.5).
U bolesnika s blagom do umjerenom bubrežnom insuficijencijom mogu biti liječeni pemetreksedom, uzimanje NSAIL-a s dugim poluvremenom eliminacije mora se prekinuti najmanje 5 dana prije, na sam dan i najmanje 2 dana nakon primjene pemetrekseda (vidjeti dio 4.5).
In patients with mildly impaired renal function (creatinine clearance 50 – 80 ml/min) no dose adjustment is required.
Kod bolesnika s blagim oštećenjem funkcije bubrega (klirens kreatinina 50 - 80 ml/min) nije potrebna prilagodba doze.
In patients with mildly impaired renal function (creatinine clearance 50 – 80 ml/min) no dose adjustment is required.
Kod bolesnika s blagim oštećenjem funkcije bubrega (klirens kreatinina 50 – 80 ml/min) nije potrebna prilagodba doze.
In patients with mildly impaired renal function (creatinine clearance 50 – 80 ml/min) no dose adjustment is required.
Kod bolesnika s blagim oštećenjem funkcije bubrega (klirens kreatinina 50-80 ml/min) nije potrebna prilagodba doze.
In patients with mild–to–moderate hepatic impairment due to cirrhosis, the dose of indinavir should be reduced to 600 mg every 8 hours.
U bolesnika s blagim do umjerenim oštećenjem funkcije jetre koje je posljedica ciroze, dozu indinavira treba smanjiti na 600 mg svakih 8 sati.
In patients with Mobilisation of PBPC
Bolesnici s mobilizacijom stanica preteča periferne krvi
In patients with moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15 - 29 ml/min) renal impairment the following dosage recommendations apply:
U bolesnika s umjereno (klirens kreatinina 30-49 ml/min) ili teško (klirens kreatinina 15-29 ml/min) oštećenom funkcijom bubrega primjenjuju se sljedeće preporuke doziranja:
In patients with moderate hypercalcaemia (albumin- corrected serum calcium <3 mmol/l or <12 mg/dl) 2 mg is an effective dose.
U bolesnika s umjerenom hiperkalcijemijom (kalcij u serumu korigiran albuminom <3 mmol/l ili <12 mg/dl) doza od 2 mg je učinkovita.
In patients with moderate hypercalcaemia (albumin-corrected serum calcium <3 mmol/l or <12 mg/dl) 2 mg is an effective dose.
U bolesnika s umjerenom hiperkalcijemijom (kalcij u serumu korigiran albuminom < 3 mmol/l ili < 12 mg/dl) doza od 2 mg je učinkovita.
In patients with moderate liver problems, the starting dose should be reduced to 0.3 mg twice a day and the maximum recommended dose is 0.6 mg twice a day.
U bolesnika s umjerenim problemima jetre, početnu dozu treba smanjiti na 0,3 mg dva puta na dan, a maksimalna preporučena doza iznosi 0,6 mg dva puta na dan.
In patients with moderate or severe renal impairment (CrCL 15 – 50 mL/min), the recommended dose is 30 mg Lixiana once daily (see section 5.2).
Za bolesnike s umjerenim ili teškim oštećenjem funkcije bubrega (CrCL 15 – 50 ml/min), preporučena doza Lixiane je 30 mg jedanput na dan (vidjeti dio 5.2).
In patients with moderate or severe renal impairment (creatinine clearance < 50 ml/min) the daily dose must be adjusted and renal function should be closely monitored (see sections 4.2 and 5.2).
U pacijenta s umjerenim ili teškim oštećenjem funkcije bubrega (klirens kreatinina < 50 ml/min) dnevna doza mora se prilagoditi, a funkcija bubrega detaljno pratiti (vidjeti dijelove 4.2 i 5.2).
In patients with moderate or severe renal impairment, or end-stage renal disease on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively. (Patients with end-stage renal disease underwent haemodialysis immediately after alogliptin dosing.
U bolesnika s umjerenim ili teškim oštećenjem bubrega, ili završnim stadijem bolesti bubrega na hemodijalizi, opaženo je povećanje sistemske izloženosti alogliptinu od približno 2 i 4 puta. (Bolesnici sa završnim stadijem bolesti bubrega su podvrgnuti hemodijalizi neposredno nakon primjene alogliptina.
In patients with moderate or severe renal impairment, or end-stage renal disease on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively. (Patients with end-stage renal disease underwent haemodialysis immediately after alogliptin dosing.
U bolesnika s umjerenim ili teškim oštećenjem bubrega, ili završnim stadijem bolesti bubrega na hemodijalizi, opaženo je povećanje sistemske izloženosti alogliptinu od približno 2 i 4 puta. (Bolesnici sa završnim stadijem bolesti bubrega su podvrgnuti hemodijalizi odmah nakon doziranja alogliptina.
In patients with moderate or severe renal impairment, or end-stage renal disease on haemodialysis, an increase in systemic exposure to alogliptin of approximately 2- and 4-fold was observed, respectively. (Patients with end-stage renal disease underwent haemodialysis immediately after alogliptin dosing.
U bolesnika s umjerenim ili teškim oštećenjem bubrega, ili završnim stadijem bolesti bubrega na hemodijalizi, opaženo je povećanje sistemske izloženosti alogliptinu od približno 2, odnosno 4 puta. (Bolesnici sa završnim stadijem bolesti bubrega su podvrgnuti hemodijalizi odmah nakon doziranja alogliptina.
In patients with moderate renal impairment (40 mL/min  CrCl  60 mL/min), the recommended dose is 280 mg/m² given once every 3 weeks.
U bolesnika s umjerenim oštećenjem bubrega (40 mL/min  CrCl  60 mL/min) preporučena doza je 280 mg/m² primijenjena jedanput svaka 3 tjedna.
In patients with moderate renal impairment (CrCL 30 to 50 mL/min, calculated by the Cockroft-Gault formula), the recommended dose of bosutinib is 400 mg daily (see sections 4.4 and 5.2).
U bolesnika s umjerenim oštećenjem funkcije bubrega (CrCL 30 do 50 ml/min, izračunato Cockroft- Gaultovom formulom), preporučena doza je 400 mg bosutiniba dnevno (vidjeti dijelove 4.4 i 5.2).
In patients with moderate renal impairment (CrCL 30-50 mL/min), there is limited clinical experience.
U skupini bolesnika s umjerenim oštećenjem bubrega (CrCL 30 - 50 mL/min) kliničko iskustvo je ograničeno.
In patients with moderate renal impairment (CrCL 30-50 mL/min), there is limited clinical experience.
U skupini bolesnika s umjerenim oštećenjem bubrega (CrCL 30-50 mL/min) kliničko iskustvo je ograničeno.
In patients with moderate renal impairment (creatinine clearance
Kod bolesnika s umjerenim oštećenjem bubrega (klirens kreatinina
In patients with moderate renal impairment (creatinine clearance
Kod bolesnika s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina
In patients with moderate renal impairment (creatinine clearance 30 - 49 ml/min) daily dose should be 10 mg (1 ml solution, equivalent to two pump actuations).
Kod bolesnika s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina 30-49 ml/min), dnevna doza bi trebala biti 10 mg (1 ml otopine, što odgovara dva potiska pumpice).
In patients with moderate renal impairment (creatinine clearance 30 - 49 ml/min) daily dose should be 10 mg per day.
Kod bolesnika s umjerenim oštećenjem bubrega (klirens kreatinina 30-49 ml/min), dnevna doza bi trebala biti 10 mg na dan.
In patients with moderate renal impairment (creatinine clearance 30 – 49 ml/min) daily dose should be 10 mg (1 ml solution, equivalent to two pump actuations).
Kod bolesnika s umjerenim oštećenjem bubrega (klirens kreatinina 30-49 ml/min), dnevna doza bi trebala biti 10 mg (1 ml otopine, istovjetno dvama pokretanjima pumpice).
In patients with moderate renal impairment (creatinine clearance 30 – 49 ml/min) daily dose should be 10 mg per day.
Kod bolesnika s umjerenim oštećenjem bubrega (klirens kreatinina 30 – 49 ml/min), dnevna doza bi trebala biti 10 mg na dan.
In patients with moderate renal impairment (creatinine clearance 30 – 49 ml/min) daily dose should be 10 mg per day.
Kod bolesnika s umjerenim oštećenjem bubrega (klirens kreatinina 30-49 ml/min) dnevna doza bi trebala biti 10 mg na dan.
In patients with moderate renal impairment (creatinine clearance 30 – 49 ml/min) daily dose should be 10 mg per day.
Kod bolesnika s umjerenim oštećenjem funkcije bubrega (klirens kreatinina 30-49 ml/min) dnevna doza bi trebala biti 10 mg na dan.
In patients with moderate renal impairment (creatinine clearance 31 to 50 ml/min), AUC increased by 44% and Cmax by 26% compared with patients with normal renal function.
U bolesnica s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina 31 do 50 ml/min), AUC se povećao za 44% i Cmax za 26% u usporedbi sa bolesnicama s normalnom bubrežnom funkcijom.
In patients with moderate renal impairment (estimated creatinine clearance  30 ml/min and  50 ml/min), varenicline exposure increased 1.5- fold compared with subjects with normal renal function (estimated creatinine clearance > 80 ml/min).
U bolesnika s umjerenim oštećenjem bubrežne funkcije (procijenjeni klirens kreatinina ≥ 30 ml/min i ≤ 50 ml/min) izloženost vareniklinu povećala se 1,5 puta u usporedbi s ispitanicima s normalnom bubrežnom funkcijom (procijenjeni klirens kreatinina > 80 ml/min).
In patients with moderate renal impairment (GFR 30-59 ml/ min) the infusion rate should be reduced to 1.4 mg/kg/h.
U bolesnika s umjerenim oštećenjem bubrežne funkcije (GFR 30-59 ml/ min) brzina infuzije mora se smanjiti na 1,4 mg/kg/h.
In patients with moderate renal impairment and concomitantly treated with dabigatran etexilate and verapamil, a dose reduction of Pradaxa to 75 mg daily should be considered (see sections 4.2 and 4.4).
U bolesnika s umjerenim oštećenjem bubrega, koji se istodobno liječe dabigatraneteksilatom i verapamilom, potrebno je razmotriti sniženje doze Pradaxe na 75 mg dnevno (vidjeti dijelove 4.2 i 4.4).
In patients with moderate renal impairment and concomitantly treated with dabigatran etexilate and verapamil, a dose reduction of Pradaxa to 75 mg daily should be considered (see sections 4.4 and 4.5).
Za bolesnike s umjerenim oštećenjem bubrega koji se istovremeno liječe dabigatraneteksilatom i verapamilom potrebno je razmotriti snižavanje doze Pradaxe na 75 mg dnevno (vidjeti dijelove 4.4 i 4.5).
In patients with moderate renal impairment topotecan plasma clearance was reduced to 34 % of the value in control patients.
U bolesnika s umjerenim oštećenjem bubrega klirens plazme za topotekan je smanjen na 34% vrijednosti kontrolne skupine.
In patients with moderate renal impairment, (creatinine clearance 30 - 50 ml/min) 100 % inhibition was achieved at 24 hours following administration of 2 microgram/kg/min.
U bolesnika s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina (GFR) 30 – 50 ml/min) postignuta je 100 % -tna inhibicija 24 sata nakon primjene 2 mikrograma/kg/min.
In patients with moderate renal impairment, (creatinine clearance 30 - 50 ml/min) 100 % inhibition was achieved at 24 hours following administration of 2 microgram/kg/min.
U bolesnika s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina 30 – 50 ml/min) postignuta je 100 % -tna inhibicija 24 sata nakon primjene 2 mikrograma/kg/min.
In patients with moderate renal impairment, (creatinine clearance 30 – 50mL/min) 100% inhibition was achieved at 24 hours following administration of 2 microgram/kg/min.
U bolesnika s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina (GFR) 30 – 50 ml/min) postignuta je 100 % -tna inhibicija 24 sata nakon primjene 2 mikrograma/kg/min.
In patients with moderate renal impairment, (creatinine clearance 30 – 50mL/min) 100% inhibition was achieved at 24 hours following administration of 2 microgram/kg/min.
U bolesnika s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina 30 – 50 ml/min) postignuta je 100 % -tna inhibicija 24 sata nakon primjene 2 mikrograma/kg/min.
In patients with moderate renal impairment, the incidence of renal- related adverse reactions was similar across all treatment groups: Zurampic 200 mg (12.7%), Zurampic 400 mg (16.3%) and placebo (13.3%).
U bolesnika s umjerenim oštećenjem funkcije bubrega, incidencija nuspojava povezanih s bubrezima bila je slična u svim terapijskim skupinama: Zurampic u dozi od 200 mg (12,7%), Zurampic u dozi od 400 mg (16,3%) i placebo (13,3%).
In patients with moderate risk of venous thromboembolism (e.g. after abdominal surgery), the recommended dose is 20 mg of enoxaparin sodium subcutaneously once daily.
U bolesnika s umjerenim rizikom za vensku tromboemboliju (npr. nakon abdominalnog kirurškog zahvata), preporučena doza je 20 mg enoksaparinnatrija supkutano jedanput na dan.
In patients with moderate to severe renal insufficiency (creatinine clearance < 50 ml/min), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels are approximately doubled.
U bolesnika s umjerenim do teškim oštećenjem bubrega (klirens kreatinina < 50 ml/min), klirens eptifibatida smanjuje se za oko 50 %, a koncentracije u plazmi u stanju dinamičke ravnoteže su približno udvostručene.
In patients with moderately reduced kidney function the doctor may need to reduce the dose.
U bolesnika s umjereno smanjenom funkcijom rada bubrega liječnik će možda morati smanjiti dozu.
In patients with moderately to severely active paediatric Crohn’s disease, the rate of anti-adalimumab antibody development in patients receiving adalimumab was 3.3%.
U bolesnika s umjerenim do teškim oblikom aktivne Crohnove bolesti, stopa stvaranja protutijela na adalimumab u bolesnika koji primaju adalimumab bila je 3,3%.
In patients with multiple myeloma, the combination of lenalidomide with dexamethasone is associated with an increased risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (predominantly myocardial infarction and cerebrovascular event).
U bolesnika s multiplim mijelomom, kombinacija lenalidomida s deksametazonom povezana je s povećanim rizikom od venske tromboembolije (pretežno duboke venske tromboze i plućne embolije) te arterijske tromboembolije (pretežno infarkta miokarda i cerebrovaskularnog događaja).
In patients with myelodysplastic syndromes and mantle cell lymphoma, treatment with lenalidomide monotherapy was also associated with a risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism), but to a lesser extent than in patients with multiple myeloma – see sections 4.5 and 4.8.
U bolesnika s mijelodisplastičnim sindromima i limfomom plaštenih stanica, monoterapija lenalidomidom bila je također povezana s rizikom od venske tromboembolije (pretežno duboke venske tromboze i plućne embolije), ali u manjoj mjeri nego što je to u bolesnika s multiplim mijelomom - vidjeti dijelove 4.5 i 4.8.
In patients with myelodysplastic syndromes and mantle cell lymphoma, treatment with lenalidomide monotherapy was also associated with a risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism), but to a lesser extent than in patients with multiple myeloma – see sections 4.5 and 4.8.
U bolesnika s mijelodisplastičnim sindromima sindromima i limfomom plaštenih stanica, monoterapija lenalidomidom bila je također povezana s rizikom od venske tromboembolije (pretežno duboke venske tromboze i plućne embolije), ali u manjoj mjeri nego što je to u bolesnika s multiplim mijelomom - vidjeti dijelove 4.5 i 4.8.
In patients with newly diagnosed CML in chronic phase
Bolesnici s novodijagnosticiranim KML-om u kroničnoj fazi
In patients with newly diagnosed dysplasia treated with Simponi, the risks and benefits to the individual patient must be carefully reviewed and consideration should be given to whether therapy should be continued.
U bolesnika s novodijagnosticiranom displazijom koji su liječeni lijekom Simponi mora se pažljivo procijeniti rizike i koristi za svakog pojedinog bolesnika te razmotriti treba li nastaviti s liječenjem.
In patients with newly diagnosed multiple myeloma aged 75 years and older who received lenalidomide, there was a higher incidence of serious adverse reactions and adverse reactions that led to treatment discontinuation (see section 4.4).
U bolesnika s novodijagnosticiranim multiplim mijelomom u dobi od 75 godina i starijih koji su primali lenalidomid, zabilježena je veća incidencija ozbiljnih nuspojava i nuspojava koje su dovele do obustave liječenja (vidjeti dio 4.4).
In patients with no detectable EGFR protein expression, no improvement in overall survival (hazard ratio [HR] = 1.52 [0.74, 3.12]) or progression free survival (hazard ratio [HR] = 1.33 [0.65, 2.70] was observed.
U bolesnika bez mjerljive ekspresije proteina EGFR nije primijećeno produljenje ukupnog preživljenja (omjer hazarda [HR] = 1,52 [0,74; 3,12]) niti preživljenja bez progresije bolesti (omjer hazarda [HR] = 1,33 [0,65; 2,70]).
In patients with non-CNS/non-testes extramedullary disease (defined as at least 1 lesion ≥ 1.5 cm) at screening (N = 8/189) clinical response rates (25% [95% CI: 3.2-65.1] were lower compared with patients with no evidence of extramedullary disease (N = 181, 43.6% [95% CI: 36.3 - 51.2]) (see figure 1).
U bolesnika koji su prilikom probira imali ekstramedularnu bolest nevezanu uz SŽS ili testise (definirano kao najmanje jedna lezija od ≥ 1,5 cm) (N = 8/189), stopa kliničkog odgovora (25% [95% CI:3,2-65,1]) bila je niža u usporedbi s bolesnicima u kojih nije bilo dokaza ekstramedularne bolesti (N = 181, 43,6% [95% CI: 36,3 – 51,2]) (vidjeti Sliku 1).
In patients with non-functional gastrointestinal or lung neuroendocrine tumours and good prognostic baseline factors, e.g. ileum as primary tumour origin and normal chromogranin A values or without bone involvement, an individual benefit-risk assessment should be performed prior to the start of Afinitor therapy.
U bolesnika s nefunkcionalnim neuroendokrinim tumorima probavnog sustava ili pluća i dobrim početnim prognostičkim čimbenicima, npr. ileumom kao primarnim sijelom tumora i normalnim vrijednostima kromogranina A ili bez zahvaćenosti kostiju, potrebno je individualno procijeniti koristi i rizike prije početka liječenja Afinitorom.
In patients with non-Hodgkin’s lymphoma and CLL, premedication with glucocorticoids should be considered if MabThera is not given in combination with glucocorticoid-containing chemotherapy.
U bolesnika s ne-Hodgkinovim limfomom i KLL-om potrebno je razmotriti premedikaciju glukokortikoidima ako se MabThera ne primjenjuje u kombinaciji s kemoterapijom koja sadrži glukokortikoide.
In patients with non-Hodgkin’s lymphoma receiving MabThera in combination with cytotoxic chemotherapy, cases of hepatitis B reactivation have been reported (see non-Hodgkin’s lymphoma).
U bolesnika s ne-Hodgkinovim limfomom koji primaju lijek MabThera u kombinaciji s citotoksičnom kemoterapijom prijavljeni su slučajevi reaktivacije hepatitisa B (vidjeti ne-Hodgkinov limfom).
In patients with non-infectious uveitis, anti-adalimumab antibodies were identified in 4.8% (12/249) of patients treated with adalimumab.
U bolesnika s neinfektivnim uveitisom, protutijela na adalimumab nađena su u 4,8% (12/249) bolesnika liječenih adalimumabom.
In patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): The optimal duration of treatment has not been formally established.
Kod bolesnika s akutnim koronarnim sindromom bez elevacije ST segmenta (nestabilna angina ili non-Q infarkt miokarda): optimalno trajanje liječenja nije formalno utvrđeno.
In patients with non-transfusion-dependent thalassaemia syndromes, treatment is started when there is evidence of iron overload.
U bolesnika sa sindromima talasemije neovisnima o transfuziji liječenje počinje kada se utvrdi da postoji preopterećenje željezom.